Kenichi Maruyama 0:03
So I'm Kenichi Maruyama, Schiele, at the GORYO Chemical from Japan. So I'd like to introduce the new intra operative diagnostic system by using navigation track. So natural drug can reduce surgical merging through real time. So, next slide shows information of damage on track down the actual drug can detect a micro countesses tissue in real time during surgery. We deliver innovation but eliminating cancerous tissues in vivo using our one minute spray. So, it has three characteristics. At first, that we should drug visualize cancerous tissue with process right, the second easy to use diversion drug achieved carrying surgical magic without pathologist, the third we enable high quality cancer treatment without adding healthcare workload. So, next slide show the therapeutic rationale the NAMSA drug can eliminate cancerous tissues by binding to a cancer specific enzyme. So, national drug is consist of HRG chemical structure. So, h murgee has already problem it safety in Japanese clinical trials as you can see hyg structure So, h Margi has a three step for detecting any counselors. First step active ingredient G Group H murgee binds to GTT has expressed in cancer cells. The second step GGT catalysis G Gu H Margi to produce process H Margi. The last lysosome quickly absorbed HRG enabling localization to the cancer cell Okay, next slide. So, if you use the actual drugs to breast cancer, the actual drug improved treatment without adding healthcare workflow bro breathing ability to non pathologist, the adaption drug rule was recurrence and the acquisition of a breast cancer as you can see background in United States. So, annual diagnosis rate is 100 100 ad Seldon per year and high recurrence caused by Intuitive Surgical versions. If you use NAMSA drug you we provide three benefit. One benefit is a bit availability increase use for no pathologist, the second savings in labor diagnosis without pathologist, the third reduced the acquisition by more complete cancer removal. Okay, next slide show our market potential. Actually, we have already investigated the market potential in United States as a result close to six 5% of surgeon interested in using the adoption drug in lumpectomy. So, this data is based on a survey of 75 subjects in the United States. As you can see, d s is shown around the 6% Oh Disha S means that duchal carcinoma inside you and both the invasive and the word it or show around the 65% receptivity. So, okay, next is next slide shows the how to use the snapshot track. It is very simple, five easy steps within a 30 minute and without pathologist, the actual drug fraud simple steps and easy to operate. But first remove tumor from the breast. And then so prepare the sample is no need no special technique big warrior does third step treat an application drug by a by a drug or spray and after 20 minutes. You can see their signal if you have the tumor. And then so and if you see a frozen signal it means a positive word not means delta it's very simple. Okay, next rise show that critical study results in Japan. So, we have already got the high efficacy regarding the duction drug to breast cancer. So, the sensitivity is around 80% and the selectivity is 91% service 50 this data are based on their first response 274 patients as you can see distribution process response. So, in this data, so above the thresholds means Malaguti net and so the area under that threshold means benign. So, as you can see the So, that's red hold a query divide up from malignant and benign okay. So, next slide show growth potential knocklyon drug provide a scalable solution. So, other tumors and diseases, various diseases could be treated with the adaption drug as is or with minor modification. So, after developing breast cancer, we have two strategies. One strategy is diseases treat it with amino acid modification. So, this means that if you are changing x part of H Margi, you can detect from exposure to cancer, chronic Qura active cancer, gastric cancer and others. So, next strategy is diseases treatable with existing substrate. Existing substrates means that the peptide the peptide is the Arielle air means leucine A means Missoni. So, mh RG can detect from MRI coma, punk rock rake and the brain tumor and round cancer by using just one MH margin. Okay, so this is the last slide. So this slide shows the regulatory update in Japan. We have the five pipelines, one pipeline is in better diagnostics, right breast cancer and the others is in vivo diagnostics. Diagnostics. So actually, we have already out right since breast cancer to termo company in Japan. And in in vivo diagnosis. Greg comer also has been authorized to send you from Stuttgart in Japan. So in this conference, we are seeking corroborate partner which can develop breast cancer in United States as well as Japan. Okay, so that's all for my presentation. Thank you very much. Thanks for your attention.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
